2 weeks Ago By Defense World Staff
Brandes Investment Partners LP lifted its stake in shares of Laboratory Co. of America Holdings ( NYSE:LH – Free Report ) by 25.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission.
The firm owned 494,068 shares of the medical research company’s stock after purchasing an additional 99,912 shares during the quarter. Brandes Investment Partners LP owned about 0.59% of Laboratory Co.
of America worth $100,609,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors have also recently made changes to their positions in LH. Price T Rowe Associates Inc.
MD boosted its position in shares of Laboratory Co. of America by 2.6% in the 1st quarter.
Price T Rowe Associates Inc. MD now owns 114,488 shares of the medical research company’s stock worth $25,012,000 after buying an additional 2,934 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Laboratory Co.
of America by 3.0% in the fourth quarter. Northern Trust Corp now owns 1,163,252 shares of the medical research company’s stock valued at $264,396,000 after purchasing an additional 33,493 shares in the last quarter.
Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Laboratory Co.
of America by 17.0% in the first quarter. Mitsubishi UFJ Asset Management Co.
Ltd. now owns 101,019 shares of the medical research company’s stock valued at $22,069,000 after purchasing an additional 14,708 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Laboratory Co.
of America by 283.1% during the 1st quarter. SG Americas Securities LLC now owns 23,217 shares of the medical research company’s stock worth $5,072,000 after purchasing an additional 17,156 shares in the last quarter.
Finally, First National Bank of Mount Dora Trust Investment Services acquired a new position in shares of Laboratory Co. of America during the 1st quarter worth approximately $1,418,000. Institutional investors and hedge funds own 95.
94% of the company’s stock. Wall Street Analysts Forecast Growth A number of equities research analysts have commented on LH shares. Jefferies Financial Group increased their target price on Laboratory Co.
of America from $245.00 to $265.00 and gave the company a “buy” rating in a report on Monday, September 23rd.
Bank of America lifted their price objective on Laboratory Co. of America from $240.00 to $260.
00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Laboratory Co. of America from $220.
00 to $230.00 and gave the company a “hold” rating in a report on Friday, August 2nd. Robert W.
Baird raised their price target on shares of Laboratory Co. of America from $278.00 to $282.
00 and gave the stock an “outperform” rating in a research note on Friday, September 20th. Finally, Truist Financial boosted their price objective on shares of Laboratory Co. of America from $255.
00 to $275.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock.
According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $254.50.
Laboratory Co. of America Price Performance Shares of Laboratory Co. of America stock opened at $222.
10 on Monday. The stock has a market capitalization of $18.72 billion, a P/E ratio of 44.
69, a PEG ratio of 1.74 and a beta of 1.06.
The company has a current ratio of 0.88, a quick ratio of 0.77 and a debt-to-equity ratio of 0.
39. The business’s fifty day moving average price is $223.55 and its 200 day moving average price is $211.
63. Laboratory Co. of America Holdings has a twelve month low of $191.
97 and a twelve month high of $238.46. Laboratory Co.
of America ( NYSE:LH – Get Free Report ) last posted its earnings results on Thursday, August 1st. The medical research company reported $3.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.
78 by $0.16. Laboratory Co.
of America had a net margin of 3.60% and a return on equity of 15.39%.
The firm had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.19 billion.
During the same quarter in the prior year, the company earned $3.42 EPS. The company’s revenue was up 6.
2% on a year-over-year basis. As a group, research analysts anticipate that Laboratory Co. of America Holdings will post 14.
61 earnings per share for the current year. Laboratory Co. of America Announces Dividend The business also recently disclosed a quarterly dividend, which was paid on Friday, September 13th.
Shareholders of record on Thursday, August 29th were paid a dividend of $0.72 per share. This represents a $2.
88 dividend on an annualized basis and a dividend yield of 1.30%. The ex-dividend date of this dividend was Thursday, August 29th.
Laboratory Co. of America’s dividend payout ratio is presently 57.95%.
Insiders Place Their Bets In related news, CFO Glenn A. Eisenberg sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $223.
99, for a total transaction of $3,359,850.00. Following the transaction, the chief financial officer now directly owns 31,289 shares of the company’s stock, valued at approximately $7,008,423.
11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink . In other Laboratory Co.
of America news, CFO Glenn A. Eisenberg sold 15,000 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $223.
99, for a total value of $3,359,850.00. Following the completion of the transaction, the chief financial officer now directly owns 31,289 shares of the company’s stock, valued at approximately $7,008,423.
11. The transaction was disclosed in a filing with the SEC, which is accessible through this link . Also, EVP Der Vaart Sandra D.
Van sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $227.05, for a total value of $454,100.
00. Following the sale, the executive vice president now owns 3,670 shares of the company’s stock, valued at $833,273.50.
The disclosure for this sale can be found here . Insiders have sold a total of 29,679 shares of company stock worth $6,716,306 over the last quarter. 0.
85% of the stock is owned by corporate insiders. About Laboratory Co. of America ( Free Report ) Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.
It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). See Also Five stocks we like better than Laboratory Co. of America Why is the Ex-Dividend Date Significant to Investors? 3 Bargain Stocks Under $20 With Major Growth Potential Best Stocks Under $10.
00 Top 5 ETFs to Own Now and Into 2025 Are These Liquid Natural Gas Stocks Ready For An Upside Bounce? Watch These 3 Former Short-Squeeze Stocks for a Big Rally Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Co. of America Holdings ( NYSE:LH – Free Report ).
Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.
com's FREE daily email newsletter ..
